Victory Capital Management Inc. Has $352,000 Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Key Points

• Victory Capital Management Inc. decreased its holdings in Nurix Therapeutics by 50.7% in the first quarter, owning 29,660 shares after selling over 30,000 shares.
• Nurix Therapeutics reported an earnings per share (EPS) of ($0.52) for the last quarter, surpassing analysts' expectations of ($0.79).
• The stock has experienced a 2.0% decrease recently, opening at $11.04, with a 52-week range of $8.18 to $29.56.

Victory Capital Management Inc. decreased its position in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 50.7% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 29,660 shares of the company's stock after selling 30,552 shares during the quarter. Victory Capital Management Inc.'s holdings in Nurix Therapeutics were worth $352,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the company. FMR LLC grew its stake in shares of Nurix Therapeutics by 1,711.9% in the 4th quarter. FMR LLC now owns 10,634,231 shares of the company's stock valued at $200,349,000 after buying an additional 10,047,329 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Nurix Therapeutics by 8.3% in the 4th quarter. Vanguard Group Inc. now owns 4,345,266 shares of the company's stock valued at $81,865,000 after buying an additional 333,452 shares in the last quarter. Wellington Management Group LLP boosted its position in Nurix Therapeutics by 3.0% during the fourth quarter. Wellington Management Group LLP now owns 3,586,605 shares of the company's stock worth $67,572,000 after purchasing an additional 104,500 shares during the period. Soleus Capital Management L.P. boosted its position in Nurix Therapeutics by 97.3% during the fourth quarter. Soleus Capital Management L.P. now owns 2,102,833 shares of the company's stock worth $39,617,000 after purchasing an additional 1,036,999 shares during the period. Finally, Geode Capital Management LLC boosted its position in Nurix Therapeutics by 9.5% during the fourth quarter. Geode Capital Management LLC now owns 1,585,127 shares of the company's stock worth $29,870,000 after purchasing an additional 137,087 shares during the period.

Insider Buying and Selling at Nurix Therapeutics

In other news, insider Gwenn Hansen sold 4,308 shares of the stock in a transaction on Wednesday, July 30th. The stock was sold at an average price of $12.01, for a total transaction of $51,739.08. Following the sale, the insider owned 69,023 shares in the company, valued at approximately $828,966.23. This represents a 5.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Houte Hans Van sold 5,402 shares of the firm's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $11.03, for a total value of $59,584.06. Following the completion of the transaction, the chief financial officer owned 35,512 shares in the company, valued at approximately $391,697.36. This represents a 13.20% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 14,014 shares of company stock worth $163,014 in the last 90 days. Company insiders own 7.40% of the company's stock.

Nurix Therapeutics Stock Down 7.0%

NASDAQ:NRIX traded down $0.79 during trading hours on Wednesday, reaching $10.52. The company had a trading volume of 419,095 shares, compared to its average volume of 879,069. The stock has a 50-day moving average of $11.88 and a two-hundred day moving average of $12.92. Nurix Therapeutics, Inc. has a one year low of $8.18 and a one year high of $29.56. The firm has a market capitalization of $804.33 million, a PE ratio of -4.05 and a beta of 2.14.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 9th. The company reported ($0.52) earnings per share for the quarter, beating analysts' consensus estimates of ($0.79) by $0.27. Nurix Therapeutics had a negative return on equity of 45.26% and a negative net margin of 234.57%. The firm had revenue of $44,056 billion for the quarter, compared to analysts' expectations of $16.26 million. As a group, sell-side analysts expect that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Morgan Stanley set a $16.00 target price on Nurix Therapeutics and gave the stock an "equal weight" rating in a research report on Tuesday, July 15th. Oppenheimer reaffirmed an "outperform" rating and set a $30.00 target price (down previously from $32.00) on shares of Nurix Therapeutics in a research report on Thursday, July 31st. UBS Group decreased their target price on Nurix Therapeutics from $30.00 to $26.00 and set a "buy" rating for the company in a research report on Thursday, July 10th. Needham & Company LLC reaffirmed a "buy" rating and set a $27.00 target price on shares of Nurix Therapeutics in a research report on Tuesday, April 29th. Finally, HC Wainwright cut their price target on Nurix Therapeutics from $36.00 to $34.00 and set a "buy" rating for the company in a report on Monday, July 14th. Four analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $28.87.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.